We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Cutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib

Veronica J. Shi, BA1; Anjela Galan, MD1,2; Ian D. Odell, MD, PhD1; Jennifer N. Choi, MD1
[+] Author Affiliations
1Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
2Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
JAMA Dermatol. 2016;152(2):222-223. doi:10.1001/jamadermatol.2015.3209.
Text Size: A A A
Published online


This case report describes the occurrence of cutaneous vasculopathy as an adverse effect of treatment with the anti–vascular endothelial growth factor agent axitinib.

Axitinib is a targeted chemotherapeutic agent against the vascular endothelial growth factor (VEGF) receptor pathway. Cutaneous toxic effects of these newer targeted therapies are increasingly being recognized. Herein we present a case of cutaneous vasculopathy associated with axitinib.

Figures in this Article

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.
Cutaneous Lesions of the Left Foot in a Patient Receiving Axitinib Therapy

Initial presentation of reticulated, purpuric patches and associated edema that affected both feet.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Histopathologic Specimens From Left Medial Foot Lesion in a Patient Receiving Axitinib Therapy

Hematoxylin-eosin–stained specimens show partial epidermal necrosis with parakeratosis, dermal fibrosis, perivascular lymphocytic infiltrate, and extravasated erythrocytes (A) and prominent perivascular lymphocytic infiltrate with lymphocytes within the vascular wall (B).

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles